RLG Secures Exclusive Rights to Distribute Hydralyte in China

RooLife Group Ltd (ASX:RLG), an e-commerce company, has been chosen by The Hydration Pharmaceuticals Company Limited (ASX:HPC) to exclusively market, sell, and distribute their Hydralyte range of electrolyte-rich products in China. This deal grants RLG exclusive distribution rights for both online and physical store sales, encompassing cross-border e-commerce and general trade within China. RLG's revenue will come from various sources, including service fees, digital marketing fees, and margins on product sales. This agreement expands RLG's involvement in the health and functional food and beverage sector in China, supplementing their existing portfolio.

The contract spans an initial term of 2 years and 5 months, with reviews of marketing investment and the potential for increased activities. The addition of Hydralyte complements RLG's position in the online sports nutrition segment, capitalizing on the thriving health and wellness market in China. RooLife Group CEO, Bryan Carr, expressed enthusiasm for this addition, highlighting RLG's aim to tap into China's growing middle class and their affinity for international quality products. Oliver Baker, CEO of The Hydration Pharmaceuticals Company, praised RLG's established online sales channels and access to a burgeoning physical store network as the ideal platform for Hydralyte's expansion in the Chinese market.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com